MX2023011880A - Factor estimulador de colonias de granulocitos modificado (g-csf) y receptores quimericos de citocinas que los unen. - Google Patents

Factor estimulador de colonias de granulocitos modificado (g-csf) y receptores quimericos de citocinas que los unen.

Info

Publication number
MX2023011880A
MX2023011880A MX2023011880A MX2023011880A MX2023011880A MX 2023011880 A MX2023011880 A MX 2023011880A MX 2023011880 A MX2023011880 A MX 2023011880A MX 2023011880 A MX2023011880 A MX 2023011880A MX 2023011880 A MX2023011880 A MX 2023011880A
Authority
MX
Mexico
Prior art keywords
variant
cytokine
receptor
methods
stimulating factor
Prior art date
Application number
MX2023011880A
Other languages
English (en)
Spanish (es)
Inventor
Brad Nelson
Megan Fuller
Martin J Boulanger
Cameron Powell
Original Assignee
Provincial Health Services Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provincial Health Services Authority filed Critical Provincial Health Services Authority
Publication of MX2023011880A publication Critical patent/MX2023011880A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2023011880A 2021-04-07 2022-04-07 Factor estimulador de colonias de granulocitos modificado (g-csf) y receptores quimericos de citocinas que los unen. MX2023011880A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163171980P 2021-04-07 2021-04-07
US202163172025P 2021-04-07 2021-04-07
US202163171933P 2021-04-07 2021-04-07
US202163171950P 2021-04-07 2021-04-07
PCT/CA2022/050540 WO2022213208A1 (en) 2021-04-07 2022-04-07 Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same

Publications (1)

Publication Number Publication Date
MX2023011880A true MX2023011880A (es) 2024-01-05

Family

ID=83544985

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011880A MX2023011880A (es) 2021-04-07 2022-04-07 Factor estimulador de colonias de granulocitos modificado (g-csf) y receptores quimericos de citocinas que los unen.

Country Status (9)

Country Link
US (1) US20240254182A1 (cg-RX-API-DMAC7.html)
EP (1) EP4320168A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024515577A (cg-RX-API-DMAC7.html)
KR (1) KR20240004453A (cg-RX-API-DMAC7.html)
AU (1) AU2022254143A1 (cg-RX-API-DMAC7.html)
CA (1) CA3213795A1 (cg-RX-API-DMAC7.html)
IL (1) IL307272A (cg-RX-API-DMAC7.html)
MX (1) MX2023011880A (cg-RX-API-DMAC7.html)
WO (1) WO2022213208A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250057883A1 (en) * 2021-12-23 2025-02-20 The Trustees Of The University Of Pennsylvania Controllable stimulation of genetically engineered lymphocytes for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695869B2 (en) * 1993-04-06 1998-08-27 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
HUP0203751A3 (en) * 2000-01-10 2005-01-28 Maxygen Holdings Ltd Redwood C G-csf conjugates
CA2737756A1 (en) * 2008-09-19 2010-03-25 Grant Yonehiro Method for the treatment of radiation-induced neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
JP7299021B2 (ja) * 2015-09-11 2023-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン/受容体ペア
US20200397821A1 (en) * 2017-03-03 2020-12-24 Exuma Biotech Corp Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
AU2019227979B2 (en) * 2018-03-02 2024-09-05 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
WO2021068068A1 (en) * 2019-10-08 2021-04-15 Provincial Health Services Authority Chimeric cytokine receptors
CA3151471A1 (en) * 2019-10-08 2021-04-15 Gesa VOLKERS Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same

Also Published As

Publication number Publication date
JP2024515577A (ja) 2024-04-10
KR20240004453A (ko) 2024-01-11
AU2022254143A1 (en) 2023-11-23
WO2022213208A1 (en) 2022-10-13
US20240254182A1 (en) 2024-08-01
CA3213795A1 (en) 2022-10-13
IL307272A (en) 2023-11-01
EP4320168A1 (en) 2024-02-14
EP4320168A4 (en) 2025-08-20

Similar Documents

Publication Publication Date Title
Waldmann et al. IL-15 in the combination immunotherapy of cancer
WO2021260209A3 (en) Ccr8 antibodies and uses thereof
MY209533A (en) Cd19 binding molecules and uses thereof
van den Brink et al. Relapse after allogeneic hematopoietic cell therapy
MX2024002657A (es) Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales.
EP4275699A3 (en) Use of the cd2 signaling domain in second-generation chimeric antigen receptors
MX2020008387A (es) Usos terapeuticos de agonistas glp1r.
SA521421188B1 (ar) بروتينات رابطة متعددة النوعية ترتبط بـ her2 -nkg2d -cd16، وطرق استخدامها
MX2022003886A (es) Dominio extracelular modificado del receptor del factor estimulante de colonias de granulocitos (g-csfr) y citocinas que lo unen.
WO2018157171A3 (en) Compositions, articles of manufacture and methods related to dosing in cell therapy
ATE453666T1 (de) Spezifische monokonjugate von g-csf
NZ702392A (en) Compositions and methods for cancer immunotherapy
MY190404A (en) Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
RU2018101316A (ru) Модель несовместимой по hla гуманизированной мыши nsg с полученным от пациента ксенотрансплантатом
EA201891341A1 (ru) Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
MX2023005353A (es) Moleculas de union a cd19 y usos de las mismas.
RU2017145940A (ru) Внутрилегочное введение полинуклеотидных агонистов толл-подобного рецептора 9 для лечения рака легких
Mortezaee et al. NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives
Almotiri CAR T-cell therapy in acute myeloid leukemia
MX2022007712A (es) Agonista doble de interleucina-2/receptor de tnf para uso en terapia.
MX2024006212A (es) Métodos para usar agonistas del rar? para tratamiento del cáncer.
Kroschinsky et al. The role of pegfilgrastim in mobilization of hematopoietic stem cells
MX2023007629A (es) Muteinas de il-2 para el tratamiento contra enfermedades autoinmunitarias e inflamatorias.
ZA202304151B (en) IL-2/IL-15RBßY AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
WO2022090202A8 (en) IL-2/IL-15Rβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER